Apart from these considerations, the LRRK2 kinase inhibitors MLi-2 and PF-066855360 have already been tested in preclinical studies [192], and there are two candidates undergoing clinical trials for PD, DNL201 and DNL151. Here, LRRK2 is linked to Parkinson disease.